OnKure Therapeutics
OKUROKUR · Stock Price
Historical price data
Overview
OnKure Therapeutics is a U.S.-based, publicly traded biotech (OKUR) focused on discovering and developing precision medicines for cancer. The company's strategy centers on building a broad pipeline of tumor-agnostic, potentially best-in-class therapies, leveraging a leadership team with a proven track record. A key recent achievement is an oversubscribed $150 million private placement in March 2026 to advance its next-generation PI3Kα inhibitor candidates in breast cancer and vascular anomalies, providing significant capital to propel its lead programs forward.
Technology Platform
Platform centered on the discovery and development of next-generation, mutant-selective small molecule inhibitors for tumor-agnostic precision oncology, with a core focus on overcoming the toxicity limitations of earlier targeted therapies.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| REN001 | Primary Mitochondrial Myopathy | Phase 2/3 | |
| Mavodelpar + Placebo | Primary Mitochondrial Myopathy | Phase 2 | |
| OKI-179 + binimetinib | RAS Mutation | Phase 1/2 | |
| REN001 | McArdle Disease | Phase 1 | |
| OKI-179 | Advanced Solid Tumors | Phase 1 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Faces direct competition from Novartis's alpelisib and multiple next-gen PI3Kα/AKT inhibitors in oncology. In the broader tumor-agnostic space, competes with large pharma and specialized biotechs targeting various oncogenic drivers, necessitating clear differentiation.